Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab with chemotherapy · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with locally recurrent unresectable or metastatic triple-negative breast cancer and PD-L1 combined positive score of at least 10 by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
This traditional conversion concerns the PD-L1-selected advanced population, separate from the same-day early-stage action.
What research teams should watch
Keep PD-L1 CPS, disease stage and treatment intent in the eligibility record.
PRIMARY RECORDS